What’s the one big standout in the health trends for 2026? We asked the experts

GLP-1–based medications such as Ozempic are the dominant trend shaping nutrition, fitness and consumer goods for 2026, with forecasts of 1.13 billion people obese by 2030 (a 115% rise from 2010) and roughly 10% of the US population expected to be on obesity drugs. Wearable tech advances (glucose, blood pressure, fall detection) and a pivot toward resistance training are being framed as commercial opportunities to mitigate up to 60% lean-mass loss observed with GLP-1 weight loss, while demographic tailwinds (more than 22% of Australians aged over 65 in 2026) and strong consumer interest in “positive ageing” and protein/personalised nutrition are likely to drive demand across food, fitness, apparel and wellness sectors.

Analysis

Market structure: GLP-1 adoption (Novo Nordisk, Eli Lilly) is a convergent demand shock touching pharmaceuticals, food manufacturers (high-protein SKUs), wearables (AAPL, ABT, DXCM) and fitness services (PTON, boutique gyms). Expect pricing power for leading GLP-1 developers to persist near-term; incumbents in processed-food/snack categories face reformulation costs and SKU mix shifts that compress gross margins by ~50-150bp over 12-24 months. Corporate winners will be platform players that capture recurring revenue (drug supply, CGM subscriptions, digital fitness).

Risk assessment: Tail risks include regulatory action (drug safety reviews, reimbursement limits) or supply-chain constraints that could cut sales 30-50% in 3-6 months; class-wide adverse events are low-probability but high-impact. Immediate volatility will cluster around quarterly results and any payer-coverage decisions in the next 30-90 days; secular adoption plays out over years (2030 market share targets). Hidden dependencies: increased protein demand raises raw-material exposure (soy, whey) and could lift related commodity prices by mid-2026.

Trade implications: Direct longs: large-cap GLP-1 innovators and integrated CGM/wearable leaders; defensive longs: protein ingredient suppliers and fitness-equipment names. Use relative-value (long fitness/equipment, short traditional weight-loss platforms) and structured options to cap downside around major catalysts (FDA/payer news). Rebalance sector exposure toward Healthcare and Select Consumer Staples over 6-24 months.

Contrarian angles: Consensus assumes uninterrupted GLP-1 share gains; missing is the muscle-loss/rehab economy upside—benefits to protein suppliers and physio/rehab services may be underpriced. Conversely, food brands over-innovating with “protein-washed” indulgence SKUs risk brand dilution and margin erosion. Historical parallels: insulin analog adoption drove durable winners (Novo) but also intense pricing/regulatory pushback—expect the same dynamic here.

Key Decisions for Investors

• Establish a 2-3% long position split 60/40 in NVO (Novo Nordisk) and LLY (Eli Lilly) over a 6-18 month horizon to capture GLP-1 secular growth; hedge with 1-1.5% notional 6–9 month call spreads (buy 12-month 10–15% OTM call, sell 6–9 month ATM call) to limit upfront cost and lock in downside.
• Initiate a 1.5% long position in AAPL and a 0.75% long in ABT (or DXCM if exposure to CGM specifically desired) to play wearables/CGM integration; enter within next 3 months ahead of product cycle, using rolling covered calls (30–45 days) to monetize near-term theta if implied vol > 25%.
• Pair trade: long 1% PTON (resistance-training/guided fitness) vs short 1% WW (weight-loss services) sized dollar-neutral for 6–12 months — rationale: GLP-1s decrease demand for program-based weight-loss while boosting demand for at-home strength equipment and subscriptions.
• Buy 6–12 month call options (10–20% OTM) on GLB (Glanbia) or POST (Post Holdings) sized 0.5–1% as a leveraged, low-cost exposure to rising demand for protein ingredients; if whey/soy commodity prices rise >15% over baseline, add to underlying equity up to 1.5%.
• Reduce exposure to legacy snack/ultraprocessed-food incumbents (e.g., GIS, K) by 1–2% over the next 12 months; require proof-point of successful high-protein SKU margin expansion (gross margin improvement >100bp sustained over two quarters) before re-adding weight.